BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX), a development stage biopharmaceutical company focused on oncology and rare diseases, will release its Q2 2025 financial results on August 14, 2025, before U.S. markets open.
The company will host a conference call at 8:30 a.m. EDT featuring CEO Philip Serlin. Investors can access the call through U.S. dial-in (+1-888-281-1167) or international dial-in (+972-3-918-0685). A live webcast and replay will be available on the company's website, with the call replay accessible until August 16, 2025.
Positive
- None.
Negative
- None.
News Market Reaction – BLRX
In the Aug 7 session, BLRX declined 6.17%, reflecting a notable negative market reaction. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com or on LinkedIn.
CONTACTS:
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025-302524198.html
SOURCE BioLineRx Ltd.